Research Topics
| W H FrishmanSummaryAffiliation: New York Medical College Country: USA Publications
| Collaborators
|
Detail Information
Publications
Drug therapies for mesenteric vascular diseaseHossein Tabriziani
Department of Medicine, St. Barnabas Hospital Center, Bronx, New York, USA
Heart Dis 4:306-14. 2002..This article outlines the appropriate medical management of ischemic disorders of the intestine, with an emphasis on the drug treatments presently used in clinical practice and those being studied in the laboratory...
Aldosterone and aldosterone antagonism in systemic hypertensionWilliam H Frishman
Department of Medicine, New York Medical College, Munger Pavilion 263, Valhalla, NY 10595, USA
Curr Hypertens Rep 6:195-200. 2004..Hyperkalemia remains a potential problem with all aldosterone antagonists...
Nicotine and non-nicotine smoking cessation pharmacotherapiesWilliam H Frishman
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
Cardiol Rev 14:57-73. 2006..Various approaches under investigation include the use of partial nicotine agonists (eg, varenicline), inhibitors of the hepatic P-450 enzyme (eg, methoxsalen), cannaboid-1 receptor antagonists (eg, rimonabant), and nicotine vaccines...
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular diseaseGautham Ravipati
Division of General Internal Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
Cardiol Rev 15:76-86. 2007..The drug will be marketed under the trade name of Revatio, not Viagra, the name used for the ED indication. The approved dose for primary pulmonary hypertension is 20 mg 3 times daily...
Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SRFranz Messerli
Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital and Columbia University, New York, NY, USA
Blood Press Suppl 1:6-9. 2007..Despite differences in the risk profiles of previously studied patients and INVEST patients, the antihypertensive effects of Ve+Tr were similar...
Vascular and heart diseases in the incumbent presidents and vice presidents of the United States of america: a medical-historical perspectiveWilliam H Frishman
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
Cardiol Rev 21:1-8. 2013..A discussion of how atrial fibrillation has affected the Presidents is also included...
Pharmacology of antiarrhythmic drugs in elderly patientsWilliam H Frishman
Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA
Clin Geriatr Med 28:575-615. 2012..Despite the large number of antiarrhythmic drugs having different electrophysiologic actions, as described in this article, only the β-blockers have been shown to be effective in reducing mortality and to lack proarrhythmic actions...
Cardiovascular drugs in pregnancyWilliam H Frishman
Department of Medicine, New York Medical College Westchester Medical Center, Munger Pavilion, Room 263, Valhalla, NY 10595, USA
Cardiol Clin 30:463-91. 2012..Many drugs are also transferred into human milk with potential adverse effects on the nursing infant. This article summarizes some of the literature concerning the risks and benefits of using cardiovascular drugs during pregnancy...
Cardiovascular pharmacologic therapies under investigation: 2012William H Frishman
Departments of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
Cardiol Rev 20:102-10. 2012..Intensive efforts over the past 45 years to develop important pharmacologic treatments have reduced CV risk dramatically. Described in this article are over 150 drugs being developed to prevent and treat CV disease...
Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimensWilliam H Frishman
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
Cardiol Rev 15:257-63. 2007..This review will discuss the impact of adherence to prescribed therapies for CVD, outline common barriers to adherence, and demonstrate the value of once-daily dosing regimens for improved patient adherence...
Are antihypertensive agents protective against dementia? A review of clinical and preclinical dataWilliam H Frishman
Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, New York 10595, USA
Heart Dis 4:380-6. 2002..In animal models, these newer agents also have been shown to prevent the progression of hypertensive microvascular damage. Their neuroprotective effects offer possible unique advantages in the management of hypertension...
Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunctionWilliam H Frishman
Departments of Medicine and Pharmacology, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
Vasc Health Risk Manag 4:1387-400. 2008..This review presents an overview of the clinical and pharmacologic carvedilol controlled-release data...
Smoking cessation pharmacotherapyWilliam H Frishman
Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, USA
Ther Adv Cardiovasc Dis 3:287-308. 2009..g. mecamylamine) and glucose tablets. Various approaches under investigation include inhibitors of the hepatic P450 enzyme (e.g. methoxsalen), cannabinoid-1 receptor antagonists (e.g. rimonabant), and nicotine vaccines...
Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncopeMarvin S Medow
Department of Pediatrics, New York Medical College, Valhalla, New York 10595, USA
Cardiol Rev 16:4-20. 2008..Treatment for recurrent vasovagal syncope includes increased salt and water intake and various drug treatments, most of which are still under investigation...
Pharmacologic management of mesenteric occlusive diseaseWilliam H Frishman
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
Cardiol Rev 16:59-68. 2008..This article outlines the appropriate pharmacologic management of ischemic disorders of the intestine, with an emphasis on the pharmacologic treatments presently being used in clinical practice and those being studied in the laboratory...
Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular diseaseWilliam H Frishman
Department of Medicine, New York Medical College, Munger Pavillion 263, Valhalla, NY 10595, USA
Expert Rev Cardiovasc Ther 2:675-81. 2004..Amlodipine/atorvastatin retains the safety and efficacy of its parent compounds whilst simplifying the management of these comorbid conditions, in what may be considered the first version of a polypill...
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparationsWilliam H Frishman
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
Prev Cardiol 10:10-22. 2007..A novel approach to treatment using the cannabinoid-1 receptor antagonist rimonabant is also under investigation...
Drug treatment of orthostatic hypotension and vasovagal syncopeWilliam H Frishman
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
Heart Dis 5:49-64. 2003..Treatment for recurrent vasovagal syncope includes increased salt intake, and various drug treatments, most of which are still under investigation...
β-Adrenergic blockersWilliam H Frishman
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY, USA
J Clin Hypertens (Greenwich) 13:649-53. 2011....
Pathophysiology and medical management of systemic hypertension in preeclampsiaWilliam H Frishman
Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
Curr Hypertens Rep 8:502-11. 2006....
beta-Adrenergic blockers: a 50-year historical perspectiveWilliam H Frishman
Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY, USA
Am J Ther 15:565-76. 2008..Indeed, the beta-adrenergic blockers have provided us with a great clinical legacy for now and in years to come...
Increased vascular compliance/decreased cardiovascular risk: what the studies tell usW H Frishman
Department of Medicine, Munger Pavilion, Room 263, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
Heart Dis 2:384-8. 2000..ACE inhibitors restore endothelial cell balance to improve arterial compliance, thus they can provide benefits beyond lowering blood pressure...
Cholesteryl ester transfer protein inhibition for coronary heart disease prevention: real hope or despair?William H Frishman
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY, USA
Am J Med 121:644-6. 2008
Statin-drug interactions: not a class effectWilliam H Frishman
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
Cardiol Rev 16:205-12. 2008..Careful consideration of the lipid lowering efficacy and also the risk profile for drug-drug interactions should be taken before initiating patients on statin therapy, or switching patients between different drugs of the statin class...
An odyssey of a clinical researcherWilliam H Frishman
Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, New York 10595, USA
Heart Dis 4:392-6. 2002
Tobacco smoking, nicotine, and nicotine and non-nicotine replacement therapiesW H Frishman
Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY 10595, USA
Heart Dis 3:365-77. 2001..Nicotine replacement and nonnicotine modalities have been used alone and in combination to help in smoking cessation. These treatment modalities appear to be safe in patients with known stable coronary artery disease...
Serotonin and the heartW H Frishman
Department of Medicine, New York Medical College, Valhalla 10595, USA
Ann Med 32:195-209. 2000..Prolongation of the ECG QT interval with 5-HT2 serotonergic receptor blockers may pose a potential risk with these treatments in some patients...
Pathophysiology and medical management of systemic hypertension and pre-eclampsia in pregnancyW H Frishman
Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA
Minerva Med 97:347-64. 2006....
Angiotensin receptor blockers for management of hypertensionDaniel F Catanzaro
Department of Medicine, SUNY, Brooklyn, NY 10203, USA
South Med J 103:669-73. 2010..The combination of clinical efficacy and tolerability should render ARBs as a major treatment alternative for hypertension...
Cardiovascular drug therapy in the elderlyWilbert S Aronow
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
Cardiol Rev 15:195-215. 2007..This article also discusses the adverse effects of cardiovascular drugs in the elderly, medications best to avoid in the elderly, and the prudent use of medications in the elderly...
Gender, ethnicity, and genes in cardiovascular disease. Part 2: implications for pharmacotherapyBenjamin M Schaefer
Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA
Heart Dis 5:202-14. 2003..Torsades de Pointes is more common in women related to a longer QT-interval. Lower dose OCPs decrease the risk of MI, stroke and thrombosis. HRTs are not effective for CAD prevention...
Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockadeW H Frishman
Departments of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
Heart Dis 3:386-97. 2001..The systemic toxicity of these agents is reviewed, along with the possible drug interactions. Brief mention is also made of other antiglaucoma medications used alone and in combination with topical beta-blockers...
A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT)William H Frishman
Department of Medicine and Pharmacology, New York Medical College, Valhalla, New York 10595, USA
Am J Hypertens 19:388-95. 2006..beta-Blockers and dihydropyridine calcium channel blockers are effective as monotherapy in hypertensive patients and have complementary mechanisms for lowering BP...
Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SRFranz Messerli
Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital and Columbia University, New York, NY, USA
Blood Press Suppl 16:6-9. 2007..Despite differences in the risk profiles of previously studied patients and INVEST patients, the antihypertensive effects of Ve+Tr were similar...
Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edemaWilliam H Frishman
Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
Am J Cardiol 89:18D-25D. 2002..Patients at risk for hypertension should be monitored for changes in blood pressure during NSAID treatment...
Innovative drug treatments for viral and autoimmune myocarditisWilliam H Frishman
Department of Medicine and Pharmacology, New York Medical College, Valhalla, NY 10595, USA
Heart Dis 4:171-83. 2002..Additionally, better means need to be established for distinguishing between viral and noninfectious autoimmune forms of the disease, so that appropriate treatment can be instituted...
Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular systemStephen J Peterson
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York, USA
Cardiol Rev 17:99-111. 2009....
Calcium channel blockers: differences between subclassesWilliam H Frishman
Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
Am J Cardiovasc Drugs 7:17-23. 2007..Representatives of both classes are now available in fixed-dose combinations containing an ACE inhibitor, the benefits of which include effective 24-hour BP control, a reduced incidence of adverse effects, and improved adherence...
Testosterone and coronary artery diseaseMonica D Schwarcz
Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
Cardiol Rev 18:251-7. 2010..The role of testosterone in male cardiovascular health is not completely understood, and additional studies are needed to explain its effect on atherosclerosis and its complications...
Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra)Charles T Stier
Department of Pharmacology, New York Medical College, Valhalla, NY 10595, USA
Heart Dis 5:102-18. 2003..Eplerenone has already been approved for the treatment of systemic hypertension, and several clinical trials are currently underway to identify other therapeutic uses for this agent in cardiovascular disease management...
U.S. medical students' perceptions of the adequacy of their schools' curricular attention to care at the end of life: 1998-2006Daniel P Sulmasy
The John J Conley Department of Ethics, St Vincent s Hospital, New York, New York 10011, USA
J Palliat Med 11:707-16. 2008..Little is known about the long-term effectiveness of recent efforts to improve end-of-life care education at U.S. medical schools...
Serum creatinine and blood urea nitrogen over a six-year period in the very old. Creatinine and BUN in the very oldD A Feinfeld
Department of Medicine, Nassau County Medical Center, East Meadow, New York, USA
Geriatr Nephrol Urol 8:131-5. 1998..Use of diuretics and NSAID by functioning elderly individuals is not necessarily associated with worsening azotemia...
Pathophysiology and medical management of systemic hypertension in pregnancyWilliam H Frishman
Department of Medicine and, New York Medical College/Westchester Medical Center, Valhalla, NY 10595, USA
Cardiol Rev 13:274-84. 2005....
Variability of response to clopidogrel: possible mechanisms and clinical implicationsTheresa Nguyen
Department of Medicine, Virginia Mason Medical Center, Seattle, Washington, USA
Cardiol Rev 14:136-42. 2006..The best laboratory procedure to screen for possible clopidogrel variability of response remains to be determined...
Exercise as a treatment modality for congestive heart failureTravis Monchamp
Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California, USA
Heart Dis 4:110-6. 2002..This article reviews the current experience with exercise and congestive heart failure and discusses strategies used to implement an exercise program for patients...
Flavanol-rich cocoa: a cardioprotective nutraceuticalRamona Mehrinfar
Department of Medicine, Harbor UCLA Medical Center, Los Angeles, California, USA
Cardiol Rev 16:109-15. 2008..This review discusses the cardioprotective properties of flavanols, and the mechanisms underlying these beneficial actions...
Treatment of hypertension and prevention of ischemic strokeWilbert S Aronow
Department of Medicine, New York Medical College, Munger Pavilion, Room 263, Valhalla, NY 10595, USA
Curr Cardiol Rep 6:124-9. 2004..The overall data also suggest that reduction of stroke in persons with hypertension is related more to a reduction in blood pressure than to the type of antihypertensive drugs used...
Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular diseaseEnzo Ragucci
Department of Medicine, The Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York 10461-2373, USA
Heart Dis 5:18-33. 2003..Various strategies to improve outcomes include the use of tight blood glucose control, and various coronary interventions are currently under clinical study...
Endothelin and endothelin antagonism: roles in cardiovascular health and diseaseP Tamirisa
Department of Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY 10461, USA
Am Heart J 130:601-10. 1995..The endothelin antagonists have great potential as agents for use in the treatment of a wide spectrum of disease entities and as biologic probes for understanding the actions of endothelin in human beings...
Ticlopidine-associated thrombotic thrombocytopenic purpuraN Naseer
Divisions of General Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA
Heart Dis 3:221-3. 2001..The patient responded successfully to plasmapheresis. The authors are reporting this case to emphasize the unpredictable nature of the association between the drug and the disease, which necessitates careful hematologic monitoring...
Antioxidant vitamins and enzymatic and synthetic oxygen-derived free radical scavengers in the prevention and treatment of cardiovascular diseaseD U Nayak
Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York, USA
Heart Dis 3:28-45. 2001..In this article, the pathogenesis of free radical production and cell injury are discussed, and therapeutic approaches for disease prevention are presented...
Inhibition of myocardial apoptosis as a therapeutic target in cardiovascular disease prevention: focus on caspase inhibitionN Guttenplan
Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA
Heart Dis 3:313-8. 2001..In addition, apoptosis in the region bordering the infarct can influence the development of ischemic cardiomyopathy and ventricular dilation...
Endothelin as a therapeutic target in the treatment of cardiovascular diseaseS Kaur
Division of General Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla 10595, USA
Heart Dis 3:176-88. 2001..Based on the promising results from animal studies, active research and drug development programs are under way to investigate the clinical potential of endothelin antagonism for treatment of cardiovascular disease...
Cardiovascular considerations with anthracycline use in patients with cancerM A Nelson
Department of Medicine, The Albert Einstein College of Medicine, Bronx, New York, USA
Heart Dis 3:157-68. 2001..Other strategies that have been evaluated are dietary glutamine supplementation and the use of the antioxidant probucol...
Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator theraHarit Desai
Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY 10595, USA
J Cardiovasc Pharmacol Ther 15:37-40. 2010..Use of CRT, statins, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers reduced mortality and hypertension, diabetes, and older age increased mortality...
Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapyHarit Desai
Department of Medicine, New York Medical College, Valhalla, 10595, USA
J Cardiovasc Pharmacol Ther 14:176-9. 2009..05), use of digoxin (risk ratio = 4.2), systemic hypertension (risk ratio = 14.2), diabetes (risk ratio = 4.3), and left ventricular ejection fraction (risk ratio = 1.1)...
Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillatorsHoang M Lai
Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY, USA
Am J Cardiol 102:77-8. 2008..In conclusion, patients with implantable cardioverter-defibrillators should be treated with beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins to reduce mortality...
Cardiovascular complications of eating disordersDeena Casiero
Department of Medicine, Montefiore Medical Center, Bronx, New York, USA
Cardiol Rev 14:227-31. 2006..Patients will require close monitoring and slower refeedings to minimize the risk of these complications...
Neuropsychiatric effects of cardiovascular drug therapySeth Keller
Department of Medicine, Division of Cardiology, Beth Israel Medical Center, New York, New York 10595, USA
Cardiol Rev 11:73-93. 2003..Since neuropsychiatric symptoms are seen in patients with cardiovascular disease, clinicians should be aware of the possible relationship between these symptoms and concurrent cardiovascular drug therapy...
Contrast-associated nephropathyVikas R Soma
Department of Medicine, Bronx VA Medical Center, Bronx, New York, USA
Heart Dis 4:372-9. 2002..The growing use of these new agents, such as acetylcysteine, endothelin blockers, and most recently fenoldopam, has increased the options available for the prevention of CaN...
Sauna as a therapeutic option for cardiovascular diseaseYen Nguyen
Department of Medicine, Stanford Medical School/Santa Clara Valley Medical Center, San Jose, CA, USA
Cardiol Rev 12:321-4. 2004..The data reported to date have been promising, but definitive studies are not possible because sauna treatment would be difficult to evaluate in a double-blind, placebo-controlled study...
Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelinesWilliam H Frishman
Department of Medicine, New York Medical College/Westchester Medical Center, Room 263 Munger Pavilion, Valhalla, NY 10595, USA
Clin Pharmacokinet 41:505-16. 2002..Despite the pharmacokinetic differences among beta-blockers, these drugs should always be titrated to achieve the desired individual patient response...
Transmyocardial revascularization: defining its roleRoss F Goldberg
Department of Surgery, St. Vincent's Medical Center, New York, NY, USA
Cardiol Rev 13:52-5. 2005..Additional studies need to be done with TMR to assess whether it is a useful treatment or an addition to the list of placebo therapies initially thought to have been of benefit in the therapy for angina pectoris...
Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertensionJung A Han
Department of Medicine, Mt Vernon Hospital, Mt Vernon, New York, USA
Cardiol Rev 16:95-108. 2008..Mention is made of other antiglaucoma medications used alone and in combination with topical beta-blockers. Identification of genetic loci-a bold new step toward glaucoma treatment-is mentioned briefly at the end of the article...
Congestive heart failure and continuous positive airway pressure therapy: support of a new modality for improving the prognosis and survival of patients with advanced congestive heart failureGary T Midelton
Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
Heart Dis 4:102-9. 2002..Other benefits include improvement in New York Heart Association functional class status and improvement in dyspnea...
Aspirin resistance: mechanisms and clinical implicationsCostas Hanjis
Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA
Cardiol Rev 14:18-25. 2006..Those individuals at high risk for aspirin resistance might best be treated with an additional oral antiplatelet drug (eg, clopidogrel) to achieve maximal protection against arterial thrombotic events...
Innovative pharmacologic approaches to cardiopulmonary resuscitationT Kelsch
Department of Medicine, New York Medical College, Westchester County Medical Center, Valhalla, New York, USA
Heart Dis 3:46-54. 2001..e., theophylline) for bradyasystolic rhythms. More innovative approaches include the use of thyroid hormone and endothelin...
Thyroid hormone and cardiovascular diseaseM Gomberg-Maitland
Department of Medicine, New York Hospital Cornell Medical Center, NY, USA
Am Heart J 135:187-96. 1998..At present there is no evidence suggesting a favorable treatment outcome using thyroid hormone supplementation for any systemic condition except in those patients with documented hypothyroidism...
Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of strokeS Warshafsky
Section of General Internal Medicine, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
J Gen Intern Med 14:763-74. 1999..Data from 13 placebo-controlled trials suggest that on average one stroke is prevented for every 143 patients treated with statins over a 4-year period...
Adrenomedullin: a vasoactive and natriuretic peptide with therapeutic potentialJ J Lah
Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
Heart Dis 2:259-65. 2000..In addition, adrenomedullin has actions in the brain, lungs, and kidneys to regulate regional hemodynamics. With these activities defined, recent studies have suggested a potential therapeutic role for adrenomedullin...
Use of pharmaceuticals in noninvasive cardiovascular diagnosisJay S Meisner
Department of Medicine, Divisions of Cardiology, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, New York, USA
Heart Dis 4:315-30. 2002..The last group reviewed includes echocardiographic contrast agents that, in this investigative setting, are employed to enhance detection of segmental wall motion when used with agents from groups 2 and 3...
The cardiac ryanodine receptor (RyR2) and its role in heart diseaseYing Taur
Department of Medicine, Long Island Jewish Medical Center/Albert Einstein College of Medicine, Manhasset, New York, USA
Cardiol Rev 13:142-6. 2005..As our understanding of this receptor and its modulators deepens, the possibility of clinical application draws near...
Prevalence of appropriate cardioverter-defibrillator shocks in 1038 consecutive patients with implantable cardioverter-defibrillatorsAdam Kruger
Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY 10595, USA
Am J Ther 16:323-5. 2009..In conclusion, patients having implantable cardioverter-defibrillators should also be treated with beta-adrenergic blockers to reduce the frequency of appropriate shocks...
Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target?William H Frishman
Department of Medicine and Pharmacology New York Medical College Westchester Medical Center, Valhalla, New York, USA
Cardiol Rev 10:199-210. 2002..In high-risk patients, the results of these most recent studies have not revealed any benefit of treatment...
Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiographyErdal Cavusoglu
Division of Cardiology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, United States
Atherosclerosis 210:226-31. 2010..High baseline plasma levels of ADMA in patients with DM have been shown to predict diabetes related complications. However, there are limited data on the prognostic significance of baseline ADMA levels in patients with established DM...
Cardiovascular effects of psychotropic drugsRobert E Feinstein
Psychiatry, New York Medical College, Valhalla, NY, USA
Curr Probl Cardiol 27:190-240. 2002
Diabetes mellitus and coronary artery disease: therapeutic considerationsJoydeep Ghosh
Division of Cardiology, Department of Medicine, Westchester Medical Center/New York Medical College, Valhalla, New York 10595, USA
Heart Dis 5:119-28. 2003....
Endothelin as a clinical target in the treatment of systemic hypertensionVinoy S Prasad
Department of Medicine, UCLA School of Medicine Harbor UCLA Medical Center, Torrance, California, USA
Cardiol Rev 17:181-91. 2009....
Cardiology patient page. Beta-adrenergic blockersWilliam H Frishman
Department of Medicine, New York Medical College, Westchester Medical Center, Munger Pavilion 263, Valhalla, NY 10595, USA
Circulation 107:e117-9. 2003
Nutriceuticals in cardiovascular disease: psylliumLavanya Petchetti
Department of Medicine, Mt Vernon Hospital, Mt Vernon, New York, USA
Cardiol Rev 15:116-22. 2007..In combination with other cholesterol-lowering drugs, such as statins, psyllium provides an added benefit on cholesterol lowering, and is well tolerated and cost-effective...
Nonpharmacologic approaches for the treatment of hyperlipidemiaTanaz Kermani
Department of Medicine, Mayo Clinic/Mayo Clinic School of Medicine, Rochester, Minnesota, USA
Cardiol Rev 13:247-55. 2005....
Therapeutic angiogenesis: a new treatment approach for ischemic heart disease--part IAnna Ahn
Department of Medicine, Long Island Jewish Medical Center Albert Einstein College of Medicine, New Hyde Park, New York, USA
Cardiol Rev 16:163-71. 2008..The results of clinical trials with growth factor infusions and gene therapy techniques to enhance growth factor production have shown some promise, but therapeutic angiogenesis remains at an early stage of development...
Cardiovascular considerations in patients undergoing gastrointestinal endoscopyChaim Ross
Department of Medicine, Division of Cardiology, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
Cardiol Rev 16:76-81. 2008..In this article, treatment recommendations are included for those patients undergoing endoscopy who are receiving anticoagulation and for those who are at risk for bacterial endocarditis...
Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskirenReza Sepehrdad
Department of Internal Medicine, UC Davis Medical Center, Sacramento, California, USA
Cardiol Rev 15:242-56. 2007....
Protein kinase C in cardiac disease and as a potential therapeutic targetStephen Murphy
Department of Internal Medicine, University of Colorado School of Medicine, Denver, CO, USA
Cardiol Rev 13:3-12. 2005....
Cardiovascular pharmacotherapeutic considerations during pregnancy and lactationShadi A Qasqas
Departments of Medicine, Washington University School of Medicine/Barnes-Jewish Hospital, St. Louis, Missouri, USA
Cardiol Rev 12:240-61. 2004..Table 2 summarizes the recommendations regarding the use of cardiovascular drugs during pregnancy and lactation...
Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulationDomenic Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
Heart Dis 5:176-81. 2003..Bioavailability was similar for both formulations of propranolol. Propranolol CR exhibited appropriate pharmacokinetics for a chronotherapeutic approach to the treatment of hypertension...
Cyclooxygenase inhibition in patients with coronary artery diseaseWilliam H Frishman
J Am Coll Cardiol 43:532-3. 2004
Comprehensive management of hypertensive emergencies and urgenciesGeorge A Mansoor
Section of Hypertension and Vascular Diseases, University of Connecticut Health Center, Farmington, Connecticut 06030 3940, USA
Heart Dis 4:358-71. 2002..Most patients respond to drug therapy, but problems may arise related to a rapid normalization of blood pressure...
Drug therapy of neurovascular diseaseJesse Weinberger
Department of Neurology, Mt Sinai Medical Center, New York, New York, USA
Cardiol Rev 11:122-46. 2003..Innovative therapies are now available for the treatment of migraine and vascular dementia. Primary prevention of stroke remains the optimal therapeutic strategy and includes treatment of systemic hypertension and hypercholesterolemia...
Chymase: a new pharmacologic target in cardiovascular diseaseChristopher Bacani
Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA
Cardiol Rev 14:187-93. 2006..Pharmacologic strategies that serve to inhibit chymase function may prove to be useful in the setting of vascular injury...
Use of diuretics in the treatment of heart failure in the elderlyDomenic A Sica
Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA, USA
Clin Geriatr Med 23:107-21. 2007....
Investigational antiplatelet drugs for the treatment and prevention of coronary artery diseaseJoshua F Zeidner
Department of Medicine, Johns Hopkins School of Medicine Johns Hopkins Hospital, Baltimore, Maryland, USA
Cardiol Rev 16:250-9. 2008....
Adverse dermatologic effects of cardiovascular drug therapy: part IWilliam H Frishman
Department of Medicine, New York Medical College, Valhalla, New York, USA
Cardiol Rev 10:230-46. 2002..For example, cardiovascular drugs can induce a vast array of adverse dermatologic responses. This article reviews the various cutaneous reaction patterns that can occur as a result of treatment with Class I and II antiarrhythmic agents...
Humor and the cardiovascular systemAra Sahakian
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, Calif, USA
Altern Ther Health Med 13:56-8. 2007
Sirolimus-eluting coronary stents: novel devices for the management of coronary artery diseaseAngela Cheng-Lai
Department of Pharmacy, Montefiore Medical Center Jack D Weiler Hospital of the Albert Einstein College of Medicine, Bronx, New York, USA
Am J Ther 11:218-28. 2004..This review article focuses on the pharmacology as well as clinical studies of the sirolimus-eluting stent...
Gender, ethnicity and genetics in cardiovascular disease: part 1: Basic principlesBenjamin M Schaefer
Department of Medicine, Jacobi Medical Center, Brooklyn, NY, USA
Heart Dis 5:129-43. 2003..In particular, genetic polymorphisms of cardiovascular candidate genes and drug metabolism are described. The pharmacodynamic and pharmacokinetic variations among genders and ethnicities are summarized...
